NCT05119296 2025-12-22Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerStanford UniversityPhase 2 Active not recruiting12 enrolled
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT05620134 2024-10-15Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerSalubris Biotherapeutics IncPhase 1/2 Active not recruiting263 enrolled